Can you take Bexarotene with Minocin for Injection?

Bexarotene has a moderate potential interaction with Cataract.

The use of bexarotene may cause new cataracts or worsening of previous cataracts. It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation. Exercise caution when using this agent in patients with a history of cataracts.

Bexarotene has a moderate potential interaction with Diabetes Mellitus.

The use of bexarotene may cause hypoglycemia in diabetic patients. It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment. Exercise caution when using this agent in diabetic patients.

The minocycline in Minocin for Injection has a moderate potential interaction with Esophageal Obstruction.

The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime. Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia. If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.

Bexarotene has a moderate potential interaction with High Cholesterol.

The use of bexarotene may cause elevations in lipids. It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established. Exercise caution when using this agent in patients with hyperlipidemia.

Bexarotene has a moderate potential interaction with Liver Disease.

In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated. It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.

The minocycline in Minocin for Injection has a moderate potential interaction with Liver Disease.

The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.

Bexarotene has a moderate potential interaction with Neutropenia.

The use of bexarotene causes neutropenia. Neutropenia is reversible after dose reduction or discontinuation of treatment. Care should be exercised in patients at risk. It is recommended to obtain complete blood counts at baseline and periodically during treatment.

The minocycline in Minocin for Injection has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

Bexarotene has a moderate potential interaction with Pancreatitis.

Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene. It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected. Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.

The minocycline in Minocin for Injection has a moderate potential interaction with Renal Dysfunction.

Tetracyclines (except doxycycline) are eliminated by the kidney to various extent. Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance. Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment. Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.

Bexarotene has a moderate potential interaction with Underactive Thyroid.

The use of bexarotene may cause hypothyroidism. It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.